Atlas Trials

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Clinical trial NCT04975061 · UNKNOWN

Trial details

NCT number
NCT04975061
Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Status
UNKNOWN
Study type
OBSERVATIONAL
Effectiveness,Safety,Thymic Cancer
Start date
2021-08-01
Primary completion
2022-12-01
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.